Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is SAD and MAD Study of AKB-9090 in Healthy Adult Participants on December 15, 2026. There are 4 upcoming events on record.
Cash runway is approximately 22 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 34 concluded trials, 88% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 15, 2026 | SAD and MAD Study of AKB-9090 in Healthy Adult Participants | Trial Milestone | Phase 1 |
| December 23, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| June 15, 2027 | A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) | Trial Milestone | Phase 2 |
| February 15, 2028 | A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G | Trial Milestone | Phase 2 |
Track AKBA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open AKBA in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.